Patents Issued in March 21, 2019
-
Publication number: 20190085281Abstract: The present invention relates to a non-powered constant-temperature cell transfer device, in which a first container, which accommodates living animal cells and a culture solution, is accommodated in a second container having a heat generating unit that emits heat generated by oxidation and reduction reactions of metal by introducing oxygen in the atmosphere in order to continuously provide an optimum culture temperature to a culture container even without being supplied with electric power, thereby maintaining activity and viability of the cells by maintaining a culture environment optimal for proliferation of the cells accommodated in the first container.Type: ApplicationFiled: September 15, 2017Publication date: March 21, 2019Inventor: HYO YOUNG LEE
-
Publication number: 20190085282Abstract: A thin film culture device for enumerating mold colonies is provided. The device comprises water-resistant first and second substrates with a growth region disposed therebetween, a dry, cold water-soluble gelling agent disposed in the growth region, and an effective amount of a calcium-chelating compound disposed in the growth region. The effective amount of calcium-chelating compound is capable of reducing a rate of lateral enlargement of the colony-forming unit growing in the culture device relative to the rate of lateral enlargement of a colony of the same mold species growing in an otherwise identical culture device that does not contain the effective amount disposed in the growth region, wherein reducing the rate of lateral enlargement of the colony-forming unit does not substantially delay detection of the colony. A corresponding method is also provided.Type: ApplicationFiled: November 20, 2018Publication date: March 21, 2019Inventor: KURT J. HALVERSON
-
Publication number: 20190085283Abstract: A method for processing biological material containing stringy tissue in a container having a tissue collector disposed in a tissue retention volume on one side of an internal filter includes washing biological material contained in the tissue retention volume with wash liquid to the tissue retention volume and allowing the wash liquid and rotating the tissue collector disposed in the tissue retention volume relative to the container in a first direction of rotation about an axis of rotation to sweep the teeth positioned on the tissue collector through the biological material and to collect stringy material on the tissue collector.Type: ApplicationFiled: November 16, 2018Publication date: March 21, 2019Inventors: William W. Cimino, Ramon Llull, Adam J. Katz
-
Publication number: 20190085284Abstract: Described herein are methods for the production of extracellular vesicles comprising culturing a population of producer cells in single-cell suspension, wherein the cells are cultured in chemically-defined culture medium, wherein the culture medium lacks animal-derived serum and animal-derived components; and obtaining from the cell culture an extracellular vesicle preparation comprising extracellular vesicles. In certain embodiments, the methods comprise perfusion culturing methods, including single-cell perfusion culturing methods and batch-refeed culturing methods. The methods described herein are a significant improvement over the state of the art and fulfills an unmet need in the field of extracellular vesicle manufacturing and quality control.Type: ApplicationFiled: September 20, 2018Publication date: March 21, 2019Inventors: Agata A. Villiger, Andrew F. Grube, Tik Yan Chan, Scott D. Estes, Kathryn E. Golden, Konstantin Konstantinov, Douglas E. Williams
-
Publication number: 20190085285Abstract: Described are medical products, methods, and cryogenic bags or other containers suitable for storing and/or transporting and/or processing cellular compositions and other related materials. In certain aspects, the contents of such cryogenic bags may be warmed, mixed, and applied to a patient. Medical products described herein find particular use in treating diseased and/or damaged tissue such as in wound repair and/or bone repair. Related methods of manufacture are also described.Type: ApplicationFiled: September 17, 2018Publication date: March 21, 2019Applicant: Muffin IncorporatedInventor: Neal E. Fearnot
-
Publication number: 20190085286Abstract: The disclose provides a cell freezing kit having a device equipped with a filter, and a container having hermetic closing means, which is capable of containing the device equipped with a filter, and methods of use thereof.Type: ApplicationFiled: September 25, 2018Publication date: March 21, 2019Applicant: GenbiotechInventors: Dominique Vacher, Jean-Noël Gouze, Yannis Guillemin
-
Publication number: 20190085287Abstract: Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof.Type: ApplicationFiled: April 12, 2018Publication date: March 21, 2019Inventors: Henry KLASSEN, Jing YANG
-
Publication number: 20190085288Abstract: Methods and compositions for the treatment of a corneal dystrophy in a subject in need thereof are provided. In one aspect, the method includes the step of obtaining a plurality of stem cells comprising a nucleic acid mutation in a corneal dystrophy target nucleic acid from the subject and manipulating the nucleic acid mutation in one or more stem cells of the plurality of stem cells to correct the nucleic acid mutation, thereby forming one or more manipulated stem cells. The manipulated stem cells are isolated and then transplanted into the subject. In some embodiments, the nucleic acid mutation is manipulated using CRISPR system.Type: ApplicationFiled: May 11, 2018Publication date: March 21, 2019Applicant: Avellino Lab USA, Inc.Inventors: Tara Moore, Andrew Nesbit, Gene Lee, Sun-young Cho, Larry DeDionisio
-
Publication number: 20190085289Abstract: Provided are methods, kits, and compositions for preparing platelet compositions suitable for infusion, including improved methods, compositions, and kits for pathogen inactivation of an apheresis-derived preparation of platelets.Type: ApplicationFiled: September 20, 2018Publication date: March 21, 2019Inventors: William GREENMAN, Adonis STASSINOPOULOS, Elan WEINER, Peter BRINGMANN, Felicia SANTA MARIA
-
Publication number: 20190085290Abstract: Method of enhancing the cellular functions characterized by the inclusion of at least the process, wherein the aqueous solution containing the cells in the low temperature sol state, in an aqueous solution that exhibits thermoreversible sol-gel transition of being a sol at low temperatures and gel at high temperatures containing at least a hydrogel-forming polymer, bringing the solution containing the to a high temperature gel and then culturing the cells under microgravity.Type: ApplicationFiled: March 14, 2017Publication date: March 21, 2019Inventors: Mori YUICHI, Yoshioka HIROSHI, Terunuma HIROSHI, Abraham SAMUEL
-
Publication number: 20190085291Abstract: It is provided a method of expanding ex vivo hematopoietic stem cells (HSC), the method comprising selecting a population of Endothelial Protein C Receptor (EPCR)+ HSC, culturing the selected HSC thereby expanding said EPCR+ HSC and the use of the expanded EPCR+ HSC for stem cells transplantation.Type: ApplicationFiled: May 31, 2017Publication date: March 21, 2019Applicants: UNIVERSITE DE MONTREAL, UNIVERSITE DE MONTREALInventors: Guy SAUVAGEAU, Iman FARES, Jalila CHAGRAOUI
-
Publication number: 20190085292Abstract: Methods and systems for enhancing cell populations such as chondrocytes for tissue engineering applications, e.g., for production of neocartilage. The methods and systems of the present invention feature the introduction of a hypotonic buffer to the cells during the cell isolation process, which results in neotissue (e.g., neocartilage) constructs that are significantly more mechanically robust as compared to those not treated with hypotonic buffer. The methods and systems may further comprise introducing cytochalasin D to cells purified with hypotonic buffer, which can further bolster the mechanical properties and matrix deposition of the cells. The methods and systems result in neocartilage engineered from chondrocytes, for example, from fetal aged tissue, having compressive properties on par with native adult articular cartilage.Type: ApplicationFiled: September 20, 2018Publication date: March 21, 2019Inventors: Kyriacos A. Athanasiou, Jerry C. Hu, Wendy E. Brown
-
Publication number: 20190085293Abstract: Methods for generating high-yield, high-purity epicardial cells are described. Wnt/?-catenin signaling is first activated in human cardiac progenitor cells, by, for example, inhibiting Gsk-3 to induce differentiation into epicardial cells. Methods for long-term in vitro maintenance of human cardiac progenitor cell-derived epicardial cells and method comprising chemically defined, xeno-free, and albumin-free culture conditions are also provided.Type: ApplicationFiled: October 10, 2018Publication date: March 21, 2019Inventors: Sean P. Palecek, Xiaoping Bao, Xiaojun Lian
-
Publication number: 20190085294Abstract: A method of obtaining a neural multipotent, unipotent or somatic cell, including: i) providing a cell of a first type which is not a neural multipotent, unipotent or somatic cell; ii) increasing expression of at least one neural multipotent or unipotent gene regulator in the cell of a first type, to a level at which the at least one neural multipotent or unipotent gene regulator is capable of driving transformation of the cell of a first type into the neural multipotent, unipotent or somatic cell, wherein the at least one multipotent or unipotent gene regulator is Musashi1 (Msi1), Neurogenin 2 (Ngn2), or both Msi1 and Ngn2; and iii) placing or maintaining the cell in a neural cell culture medium and maintaining sufficient intracellular levels of the at least one multipotent or unipotent gene regulator for a sufficient period of time to allow a stable neural multipotent, unipotent or somatic cell to be obtained.Type: ApplicationFiled: November 19, 2018Publication date: March 21, 2019Inventors: Jan-Eric Ahlfors, Rouwayda El-Ayoubi
-
Publication number: 20190085295Abstract: The present invention relates to generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors. The present invention also relates to functional beta cells produced by said methods and uses of said beta cells.Type: ApplicationFiled: February 24, 2017Publication date: March 21, 2019Applicant: Novo Nordisk A/SInventors: Nicolaj Stroeyer Christophersen, Ulrik Doehn, Mattias Hansson
-
Publication number: 20190085296Abstract: The present disclosure provides a method of producing and expanding human pancreas progenitor cells using, for example, iPSC derived cells and a human feeder cell conditioned medium. In one embodiment, cardiac mesenchyme cells are employed as feeder cells and those cells secrete growth factors, such as one or more of FGF10, KGF, or EGF, that promote pancreatic bud formation and expansion during development. In one embodiment, feeder cells are isolated from human stem cells, e.g., a human iPS-derived cardiac cells, and used to condition media and promote the growth and proliferation of iPSc derived pancreatic progenitor cells (in a feeder-free system).Type: ApplicationFiled: September 20, 2018Publication date: March 21, 2019Inventor: Sergio Mora
-
Publication number: 20190085297Abstract: Provided are suspension-based cell culture systems and media for the timely and efficient proliferation of human tumor cell clusters from a patient, and related methods of evaluating the potential responsiveness of the tumor cells and the patient to one or more therapeutic agents.Type: ApplicationFiled: March 9, 2017Publication date: March 21, 2019Inventors: Yiyou CHEN, Zhen YANG, Yihong ZHANG
-
Publication number: 20190085298Abstract: Synthetic inert 3D gel culture systems are described that can be finely tuned to exhibit desired and predetermined physical, chemical, mechanical, and biochemical properties. The culture system can be utilized to study the effect of microenvironmental factors on cancer cell response, and in particular on cancer stem cell (CSC) response. Cancer cells can be encapsulated in a crosslinked gel system having a narrow range of predetermined gel stiffness. One or more biochemical factors including peptides that can affect the growth, development, and/or proliferation of CSCs can be incorporated in the system to examine the effects of the factor(s) on the encapsulated cells with regard to growth, proliferation, size, etc.Type: ApplicationFiled: November 30, 2018Publication date: March 21, 2019Inventor: Esmaiel Jabbari
-
Publication number: 20190085299Abstract: The purpose of the invention is to provide novel cell culture substrates, cell culture vessels, and methods for cell culture. A cell culture substrate having a planar mesh structure, the substrate being coated with a polymer, is provided. Cells are cultured in a cell culture vessel having this substrate.Type: ApplicationFiled: September 6, 2018Publication date: March 21, 2019Inventors: Maiko TANABE, Shizu TAKEDA, Masahiro OKANOJO, Hiroko HANZAWA, Masao WASHIZU, Kennedy Omondi OKEYO
-
Publication number: 20190085300Abstract: In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane,and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.Type: ApplicationFiled: September 26, 2016Publication date: March 21, 2019Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.Inventors: Michael WOLFF, Michael Martin PIELER, Udo REICHL, Pavel MARICHAL-GALLARDO
-
Publication number: 20190085301Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.Type: ApplicationFiled: August 8, 2018Publication date: March 21, 2019Applicant: University of MassachusettsInventors: Guangping Gao, Li Zhong
-
Publication number: 20190085302Abstract: A recombinant virus is obtained by mutating a codon that encodes a tyrosine residue at position 385 of NP protein in the genome of influenza A virus to a codon of phenylalanine residue. The virus WSN-Y385F is a temperature-sensitive virus that can normally replicate and survive at 37° C., and cannot normally replicate and cannot survive at 33° C. Phosphorylation of a NP protein of influenza A virus can be inhibited by mutating an amino acid residue at position 385 from N terminal of the NP protein of influenza A virus, from a tyrosine to a phenylalanine. The recombinant virus can be used in analyzing mechanisms of infection by influenza virus, and in connection with methods of prevention and treatment of infection by influenza virus.Type: ApplicationFiled: January 22, 2017Publication date: March 21, 2019Inventors: Wenjun LIU, Weinan ZHENG, Jing LI
-
Publication number: 20190085303Abstract: Described herein are fusion proteins including methanol dehydrogenase (MeDH) and at least one other polypeptide such as 3-hexulose-6-phosphate dehydrogenase (HPS) or 6-phospho-3-hexuloisomerase (PHI), such as DHAS synthase or fructose-6-Phosphate aldolase or such as DHA synthase or DHA kinase. In a localized manner, the fusion protein can promote the conversion of methanol to formaldehyde and then to a ketose phosphate such as hexulose 6-phosphate or then to DHA and G3P. When expressed in cells, the fusion proteins can promote methanol uptake and rapid conversion to the ketose phosphate or to the DHA and D3P, which in turn can be used in a pathway for the production of a desired bioproduct. Beneficially, the rapid conversion to the ketose phosphate or to the DHA and G3P can avoid the undesirable accumulation of formaldehyde in the cell.Type: ApplicationFiled: October 27, 2016Publication date: March 21, 2019Inventors: Nelson R. Barton, Jingyi Li, Joseph R. Warner, Priti Pharkya
-
Publication number: 20190085304Abstract: A method for preparing powdery superoxide dismutase (SOD) hydrolysates. SOD is hydrolyzed by cellulase and then further hydrolyzed with a solution containing a mixture of proteases. Organic citric acid is added in the SOD hydrolysates solution, then the solution is freeze-dried to obtain the powdery SOD hydrolysates.Type: ApplicationFiled: September 19, 2017Publication date: March 21, 2019Inventor: Lijun QING
-
Publication number: 20190085305Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.Type: ApplicationFiled: May 29, 2018Publication date: March 21, 2019Inventors: Aldis Darzins, Lance Encell, Tonny Johnson, Dieter Klaubert, Georgyi V. Los, Mark McDougall, Keith V. Wood, Monika G. Wood, Chad Zimprich
-
Publication number: 20190085306Abstract: The present invention relates to lipase variants and methods of obtaining them. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: September 26, 2018Publication date: March 21, 2019Applicant: NOVOZYMES A/SInventors: Luise Erlandsen, Carsten Hoerslev Hansen, Jesper Vind, Allan Svendsen, Carsten Peter Sonksen
-
Publication number: 20190085307Abstract: Provided are a mismatch-specific cleavage reaction using a novel heat-resistant mismatch nuclease, a method for removing errors in a nucleic acid amplification reaction using the mismatch nuclease, a method for inhibiting the amplification of a nucleic acid having a specific base sequence during a nucleic acid amplification reaction, and a method for detecting a nucleic acid having a single-base polymorphic mutation using this inhibition method.Type: ApplicationFiled: September 26, 2018Publication date: March 21, 2019Applicant: TAKARA BIO INC.Inventors: Kiyoyuki MATSUMURA, Nariaki TAKATSU, Takashi UEMORI, Hiroyuki MUKAI
-
Publication number: 20190085308Abstract: Provided herein are methods of using a Cas1 polypeptide to generate nucleic fragments from a DNA substrate. These methods may be performed in vitro or in vivo. Also provided are methods of screening for modulators of Cas1.Type: ApplicationFiled: October 1, 2018Publication date: March 21, 2019Inventors: Blake Wiedenheft, Kaihong Zhou, Jennifer A. Doudna
-
Publication number: 20190085309Abstract: The present invention relates to cellobiohydrolase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.Type: ApplicationFiled: March 2, 2017Publication date: March 21, 2019Applicant: Novozymes A/SInventors: Mark Wogulis, Leslie Demars, Aubrey Jones, Hanshu Ding, David Osborn
-
Publication number: 20190085310Abstract: The invention relates to a process for producing cellulolytic or hemicellulolytic enzymes comprising A growth phase a) of a cellulolytic microorganism in a closed reactor, in the presence of at least one carbonaceous growth substrate in a concentration between 10 and 90 g/L, at a temperature of 25-30° C. and a pH of 4-5.5 An enzyme production phase b) in which at least one inducer carbonaceous substrate is added, at a temperature of 25-27° C. and a pH of 4-5, process in which the said inducer substrate is a pretreated pomace obtained from a pretreatment process of lignocellulosic material that has not undergone enzymatic hydrolysis and that is added in fed-batch or continuous mode, and which has particular characteristics: a hydrolysis yield greater than 80% in a test and an apparent viscosity, measured in the test, of less than 1 Pa·s for a shear rate of 10 s?1.Type: ApplicationFiled: March 24, 2017Publication date: March 21, 2019Applicants: IFP Energies nouvelles, AGRO INDUSTRIES RECHERCHE ET DEVELOPPEMENT, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUEInventors: Mohamed Fadhel BEN CHAABANE, Celine COHEN
-
Publication number: 20190085311Abstract: Reported herein is a sortase comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 11 and that comprises the mutations D101S and K137S.Type: ApplicationFiled: September 27, 2018Publication date: March 21, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Mara Boenitz-Dulat, Martin Schatte
-
Publication number: 20190085312Abstract: A treatment method is provided in which glioblastoma is targeted by administering to a subject in an effective amount theranostic cross-linked iron oxide nanoparticles (CLIO) which are conjugated to a vascular disrupting agent (ICT) and secured with a matrix-metalloproteinase cleavable peptide.Type: ApplicationFiled: November 15, 2018Publication date: March 21, 2019Inventor: Heike E. Daldrup-Link
-
Publication number: 20190085313Abstract: Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are DNA for coding the improved nitrile hydratase, a recombinant vector that contains the DNA, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase. Also provided is a method for producing an amide compound that uses the culture or a processed product of the culture. The improved nitrile hydratase contains an amino acid sequence represented by SEQ ID NO: 50 (GX1X2X3X4DX5X6R) in a beta subunit, and is characterized in that X4 is an amino acid selected from a group comprising cysteine, aspartic acid, glutamic acid, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, serine and threonine.Type: ApplicationFiled: November 30, 2018Publication date: March 21, 2019Applicant: Mitsubishi Chemical CorporationInventors: Fumiaki WATANABE, Ai Hara, Takanori Ambo, Aya Kitahara
-
Publication number: 20190085314Abstract: The present disclosure provides for peptides derived from membrane-anchored ubiquitin-fold proteins (MUB), particularly those containing a Lap-Bar-Lopp motif, for use in inhibiting ubiquitinylation.Type: ApplicationFiled: March 24, 2017Publication date: March 21, 2019Applicant: Saint Louis UniversityInventors: Brian DOWNES, Sergey V. KOROLEV, Xiaolong LU
-
Publication number: 20190085315Abstract: The present invention provides methods of increasing the efficiency of genome editing.Type: ApplicationFiled: March 23, 2017Publication date: March 21, 2019Inventors: Alan D'ANDREA, Markus GROMPE
-
Publication number: 20190085316Abstract: A process for separating prokaryotic DNA from eukaryotic DNA in a whole blood sample infected by pathogen is provided. The process includes extracting prokaryotic and eukaryotic DNA from the whole blood sample, contacting the prokaryotic DNA in the whole blood sample with a motif that specifically binds to the prokaryotic DNA, and generating a bound pair. The process also includes separating the bound pair. The whole blood sample is transfected with bacteriophages genetically modified to contain a defined DNA sequence having a selectable marker DNA. The DNA sequence integrates into the prokaryotic DNA, and the motif is an oligonucleotide specific to the defined DNA sequence in the engineered bacteriophages.Type: ApplicationFiled: August 18, 2015Publication date: March 21, 2019Inventors: Subhadra Rukmini Jayaraman, Ramya Vutukuru
-
Publication number: 20190085317Abstract: A method collects a nucleic acid from a biological sample and includes the steps of: a) mixing a support including a water-soluble neutral polymer adsorbed on a cerium oxide surface thereof with a solution containing a nucleic acid to adsorb the nucleic acid to the support; b) separating the support on which the nucleic acid was adsorbed from the solution mixed in step a); and c) collecting the nucleic acid by adding an eluent to the support on which the nucleic acid was adsorbed and which is separated in step b).Type: ApplicationFiled: March 16, 2017Publication date: March 21, 2019Inventors: Shota Sekiguchi, Shinjiro Sawada, Mai Nakagawa
-
Publication number: 20190085318Abstract: The invention provides methods for capturing target nucleic acid directly from bodily fluid samples, without the need for certain complex sample preparation steps, using Cas endonuclease to bind to the target nucleic acid sequences. The Cas proteins, along with their sequence-specific guide RNAs, may be introduced directly into the sample, where the Cas proteins bind to ends of a target nucleic acid. The target nucleic acid is thus isolated or enriched in a sequence-specific manner. The target nucleic acid may then be subject to any suitable detection or analysis assay, such as amplification or sequencing. The target nucleic acid may be enriched by digesting other, unbound nucleic acids present in the sample with exonuclease. The bound Cas proteins prevent exonuclease from digesting the target nucleic acid, thereby leaving the only the target nucleic acid substantially present in the sample.Type: ApplicationFiled: November 2, 2018Publication date: March 21, 2019Inventor: Anthony P. Shuber
-
Publication number: 20190085319Abstract: A method of preparing a nucleic acid sample with target enrichment uses a reaction vessel, within which is added a chelating agent to a sample with heating to about 99° C. to provide a crude lysate. A PNA probe is provided at a concentration sufficient for binding and capture of discernible levels of target nucleic acid. The PNA probe may be attached to beads which are initially embedded in a wax body and are released during the heating so that the y are free to move and come into contact with the PNA probe and target DNA. After binding has occurred, the beads are magnetically attracted back into a pocket along with the wax, which is allowed to solidify before they are removed from the reaction vessel.Type: ApplicationFiled: November 20, 2018Publication date: March 21, 2019Applicant: ALTRATECH LIMITEDInventors: Brian O'FARRELL, Timothy CUMMINS, Cian Desmond O'SULLIVAN, Jorge ÁLVAREZ-VICENTE
-
Publication number: 20190085320Abstract: A method of preparing a nucleic acid sample with target enrichment uses a reaction vessel, within which is added a chelating agent to a sample with heating to about 99° C. to provide a crude lysate. A PNA probe is provided at a concentration sufficient for binding and capture of discernible levels of target nucleic acid. The PNA probe may be attached to beads which are initially embedded in a wax body and are released during the heating so that the y are free to move and come into contact with the PNA probe and target DNA. After binding has occurred, the beads are magnetically attracted back into a pocket along with the wax, which is allowed to solidify before they are removed from the reaction vessel.Type: ApplicationFiled: November 20, 2018Publication date: March 21, 2019Applicant: ALTRATECH LIMITEDInventors: Brian O'FARRELL, Timothy CUMMINS, Cian Desmond O'SULLIVAN, Jorge ÁLVAREZ-VICENTE
-
Publication number: 20190085321Abstract: A molecular filter that may include a substrate. The substrate may define a first channel, a second channel, at least one slit fluidically coupling the first channel to the second channel, at least one inlet port fluidically coupled to the first channel, at least one recovery port fluidically coupled to the first channel, at least one purge port fluidically coupled to the first channel, and at least one filtrate port fluidically coupled to the second channel. A respective cross-sectional area of each respective slit of the at least one slit in a plane perpendicular to a long axis of the respective slit is smaller than a cross-sectional area of the first channel in a plane perpendicular to a long axis of the first channel.Type: ApplicationFiled: September 19, 2018Publication date: March 21, 2019Inventors: Kevin David Dorfman, Pranav Agrawal
-
Publication number: 20190085322Abstract: The purpose of the present invention is to provide a high-speed in vitro screening method for any library selected from the group consisting of a cDNA display library and a nucleic acid aptamer library. This high-speed in vitro screening method involves: (i) a step for preparing positive spherical structures formed by immobilizing a target molecule on a spherical structure and negative spherical structures having no target molecules immobilized thereon; (ii) a step in which a target detection molecule, selected from the aforementioned library having a library size of greater than or equal to 1010, is bonded on each spherical structure to obtain spherical conjugates; (iii) a step in which the spherical conjugates are sorted into positive spherical conjugates and negative spherical conjugates with a cell sorter; (v) a step for supplying the nucleic acid on the surface of the sorted spherical conjugates for PCR; (vi) and a repetition step for repeating steps (ii) to (v) above using DNA obtained by PCR.Type: ApplicationFiled: September 28, 2018Publication date: March 21, 2019Applicant: EPSILON MOLECULAR ENGINEERING INC.Inventors: Naoto NEMOTO, Toshiki MIYAJIMA, Yuta MATSUKAWA
-
Publication number: 20190085323Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized in having a specific CS combination and a specific sequence in each CDR. The present scFv library is useful in efficiently producing different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.Type: ApplicationFiled: November 28, 2018Publication date: March 21, 2019Applicant: Academia SinicaInventors: An-Suei Yang, Jhih-Wei Jian, Hong-Sen Chen, Yi-Kai Chiu, Hung-Pin Peng, Chao-Ping Tung, Chung-Ming Yu, Wei-Ying Kuo, Hung-Ju Hsu
-
Publication number: 20190085324Abstract: The present invention provides tools and methods for the systematic analysis of genetic interactions, including higher order interactions. The present invention provides tools and methods for combinatorial probing of cellular circuits, for dissecting cellular circuitry, for delineating molecular pathways, and/or for identifying relevant targets for therapeutics development.Type: ApplicationFiled: April 27, 2018Publication date: March 21, 2019Inventors: Aviv Regev, Brittany Adamson, Brian Cleary, Le Cong, Atray Dixit, Jellert Gaublomme, Eric S. Lander, Thomas Norman, Oren Parnas, Orit Rozenblatt-Rosen, Alexander K. Shalek, Jonathan Weissman
-
Publication number: 20190085325Abstract: An expression cassette for conditional expression of a single guide RNA (sgRNA) of a CRISPR/Cas9 system, the cassette includes a promoter, an sgRNA sequence, and a sequence flanked by at least a pair of recombinase recognition sites, wherein recombinase activated re-combination at the pair of recombinase recognition sites is capable of excising said flanked sequence, whereby either i) at least one of said recombinase recognition sites is located within the sgRNA sequence and said flanked sequence contains an transcription disruption sequence or ii) said flanked sequence is at least a part of the promoter or of the sgRNA sequence; methods of conditional expression of sgRNA and a reaction product of the conditional expression, i.e. sgRNA with a recombination site remnant.Type: ApplicationFiled: March 17, 2017Publication date: March 21, 2019Inventors: Ulrich ELLING, Krzysztof CHYLINSKI, Maria HUBMANN, Monika BOROWSKA, IVANA BILUSIC-VILAGOS
-
Publication number: 20190085326Abstract: A CRISPR-endonuclease gene editing composition includes a guide RNA (gRNA) for targeting a specific viral sequence for cleavage by the endonuclease which introduces breaks in the double stranded DNA identified by the gRNA. Placing the gene encoding Cas9 under the control of a minimal promoter of, for example, HIV spanning the 5?-LTR, results in the activation by the HIV-1 transactivator protein, Tat. Co-expression of both a multiplex of, for example, HIV-specific gRNAs and endonuclease, e.g. Cas9, in cells results in the modification and/or excision of the segment of viral DNA, leading to the eradication of the virus in vitro and in vivo.Type: ApplicationFiled: December 3, 2018Publication date: March 21, 2019Inventors: Kamel Khalili, Wenhui Hu, Rafal Kaminski, Thomas Malcolm
-
Publication number: 20190085327Abstract: The present invention provides a method of synthesizing, processing, and/or delivering miRNA or its precursors to eukaryotic cells using bacteria, preferably non-pathogenic or therapeutic strains of bacteria, to effect gene modulation in eukaryotic cells.Type: ApplicationFiled: July 25, 2018Publication date: March 21, 2019Inventor: Chiang LI
-
Publication number: 20190085328Abstract: The present invention provides compositions for RNA interference and methods of use thereof. In particular, the invention provides small interfering RNAs (siRNAs) having modification that enhance the stability of the siRNA without a concomitant loss in the ability of the siRNA to participate in RNA interference (RNAi). The invention also provides siRNAs having modification that increase targeting efficiency. Modifications include chemical crosslinking between the two complementary strands of an siRNA and chemical modification of a 3? terminus of a strand of an siRNA. Preferred modifications are internal modifications, for example, sugar modification, nucleobase modification and/or backbone modifications. Such modifications are also useful, e.g., to improve uptake of the siRNA by a cell. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured.Type: ApplicationFiled: August 21, 2018Publication date: March 21, 2019Inventor: Tariq M. Rana
-
Publication number: 20190085329Abstract: Isolation or in vitro assembly of the Cas9-crRNA complex of the Streptococcus thermophilus CRISPR3/Cas system and use for cleavage of DNA bearing a nucleotide sequence complementary to the crRNA and a proto-spacer adjacent motif. Methods for site-specific modification of a target DNA molecule using an RNA-guided DNA endonuclease comprising at least one RNA sequence and at least one clan RuvC active site motif and an HNH active site motif; for conversion of Cas9 polypeptide into a nickase cleaving one strand of double-stranded DNA by inactivating one of the active sites (RuvC or HNH) in the polypeptide by at least one point mutation; for assembly of active polypeptide-polyribonucleotides complex in vivo or in vitro; and for re-programming a Cas9-crRNA complex specificity in vitro or using a cassette containing a single repeat-spacer-repeat unit.Type: ApplicationFiled: October 1, 2018Publication date: March 21, 2019Applicant: Vilnius UniversityInventors: Virginijus {hacek over (S)}IK{hacek over (S)}NYS, Giedrius Gasiunas, Tautvydas Karvelis
-
Publication number: 20190085330Abstract: Several miRNAs are described that are useful in diagnosing and treating prostate cancer, or pancreatic cancer. The miRNAs bind with targets that are associated with prostate cancer or pancreatic cancer. This permits the identification of those targets as well as a treatment methodology for prostate cancer.Type: ApplicationFiled: November 26, 2018Publication date: March 21, 2019Inventors: Olorunseun O. Ogunwobi, Dibash K. Das